Key facts
- The FDA approved Revolution Medicines' Rasonque (daraxonrasib) for adults with metastatic pancreatic cancer.
- Rasonque is a first-in-class oral pill that blocks mutated RAS proteins fueling tumor growth in over 90% of pancreatic cancer cases.
- Patients on Rasonque lived a median of 13.2 months, nearly double the 6.7 months seen with standard chemotherapy.
- The drug targets a specific genetic cause of pancreatic cancer, a disease with a low five-year survival rate of 13%.
- The FDA granted expedited approval for Rasonque, more than six months ahead of its target date.
The U.S. Food and Drug Administration has approved Revolution Medicines' Rasonque (daraxonrasib) for adults with advanced pancreatic cancer. This approval marks a significant advancement for a disease with historically low survival rates, offering a new treatment option that targets a specific genetic driver of tumor growth.
Rasonque is a first-in-class oral pill designed to block mutated RAS proteins, which are implicated in over 90% of pancreatic cancer cases. In clinical trials, patients treated with Rasonque experienced a median overall survival of 13.2 months, nearly double the 6.7 months observed with standard chemotherapy. This development is particularly notable given pancreatic cancer's grim five-year survival rate of just 13%.
The FDA granted expedited approval to Rasonque, reflecting its potential to address a critical unmet need. The drug's success in a Phase 3 trial is a landmark achievement, as it is the first RAS inhibitor to reach this stage of clinical development with positive results. This breakthrough follows years of scientific research into the biology and pathways driving pancreatic cancer.
Several other companies, including Erasca, Immuneering, and Actuate Therapeutics, are also developing similar drugs targeting the KRAS gene and its associated pathways. The progress in understanding these mechanisms has led to a growing pipeline of potential treatments, offering a renewed sense of hope for patients and oncologists alike. The success of Rasonque is expected to spur further innovation in the field, with projections for its use in second-line treatment by the end of the third quarter.